Trial Outcomes & Findings for A Study of [14C]-LY3023703 in Healthy Participants (NCT NCT01965782)

NCT ID: NCT01965782

Last Updated: 2018-08-28

Results Overview

• Recruitment status: TERMINATED
• Study phase: PHASE1
• Target enrollment: 18 participants
• Primary outcome timeframe: Predose up to 168 hours post dose
• Results posted on: 2018-08-28

Participant Flow

18 subjects were screened and enrolled but no drug was given or other data collected due to the study being terminated.

Participant milestones

Measure	[^14C]-LY3023703 Single dose of 15 mg LY3023703, containing approximately 100 µCi \[\^14C\] labeled drug, administered as an oral solution.
Overall Study STARTED	0
Overall Study COMPLETED	0
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

A Study of [14C]-LY3023703 in Healthy Participants

Baseline characteristics by cohort

Baseline data not reported

PRIMARY outcome

Timeframe: Predose up to 168 hours post dose

Population: No drug was given or data collected due to the study being terminated.

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Predose up to 168 hours post dose

Population: No drug was given or data collected due to the study being terminated.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose up to 168 hours post dose

Population: No drug was given or data collected due to the study being terminated.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose up to 168 hours post dose

Population: No drug was given or data collected due to the study being terminated.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose up to 168 hours post dose

Population: No drug was given or data collected due to the study being terminated.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Predose up to 168 hours post dose

Population: No drug was given or data collected due to the study being terminated.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: One hour post-dose up to 72 hours post dose

Population: No drug was given or data collected due to the study being terminated.

Outcome measures

Outcome data not reported

Adverse Events

[^14C]-LY3023703

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Chief Medical Officer

Eli Lilly and Company

Phone: 800-545-5979

Results disclosure agreements

• Principal investigator is a sponsor employee
• Publication restrictions are in place

Restriction type: GT60